|
|
|
PBYI - Puma Biotechnology, Inc
Puma Biotechnology Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The company's primary product is Nerlynx (neratinib), an oral, small molecule tyrosine kinase inhibitor for the extended adjuvant treatment of HER2-positive early stage breast cancer.
Puma Biotechnology was founded in 2010 and is headquartered in Los Angeles, California. The company's mission is to develop innovative cancer therapies that improve patient outcomes. Puma Biotechnology has a strong commitment to patient advocacy and education, and works closely with patient groups to ensure that its products meet the needs of patients.
As of 2021, Puma Biotechnology has one approved product, Nerlynx, which is marketed in the United States, Europe, and other countries. The company has several ongoing clinical trials for Nerlynx, as well as other product candidates in various stages of development. The company's research and development efforts are focused on identifying new treatment options for patients with cancer.
In terms of financials, Puma Biotechnology reported a net loss of $54.7 million in 2020, compared to a net loss of $203.7 million in 2019. The company's total revenue for 2020 was $244.5 million, primarily driven by sales of Nerlynx. Puma Biotechnology has a market capitalization of approximately $1.3 billion as of February 2023.
|
|
|
|
|
